Short Interest in Genmab A/S (NASDAQ:GMAB) Increases By 32.5%

Genmab A/S (NASDAQ:GMAB) was the target of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 3,060,000 shares, an increase of 32.5% from the February 28th total of 2,310,000 shares. Based on an average daily volume of 1,460,000 shares, the short-interest ratio is currently 2.1 days. Currently, 0.5% of the company’s shares are short sold.

Genmab A/S Stock Down 2.9 %

GMAB stock traded down $0.57 during midday trading on Tuesday, hitting $19.02. The company’s stock had a trading volume of 754,303 shares, compared to its average volume of 957,581. The firm has a 50-day simple moving average of $20.87 and a 200-day simple moving average of $21.79. The firm has a market capitalization of $12.58 billion, a P/E ratio of 10.93, a PEG ratio of 2.65 and a beta of 0.98. Genmab A/S has a 52-week low of $18.64 and a 52-week high of $30.50.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, sell-side analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. Leerink Partnrs raised shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Leerink Partners upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.33.

Institutional Trading of Genmab A/S

Large investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in shares of Genmab A/S by 94.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock valued at $636,000 after purchasing an additional 12,654 shares in the last quarter. AIMZ Investment Advisors LLC acquired a new stake in Genmab A/S in the fourth quarter valued at $3,525,000. HighTower Advisors LLC purchased a new stake in Genmab A/S during the 3rd quarter worth about $273,000. Verition Fund Management LLC acquired a new position in shares of Genmab A/S during the 3rd quarter worth about $709,000. Finally, FMR LLC increased its holdings in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock valued at $6,782,000 after acquiring an additional 33,076 shares during the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.